Search results for "Highlights"

Results 11 - 20 of about 379 for "Highlights".
Sort by: Relevance | Newest | Oldest

Cystatin C levels associated with risk of sight-threatening diabetic retinopathy

The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
13 May 2022

HbA1c, CGM data significantly differed in patients with kidney disease

Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
13 May 2022

Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists

One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
13 May 2022

Update in Endocrinology highlights top diabetes research of 2013

Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
13 Jun 2014

Review finds blood pressure-lowering effects weaker in patients with type 2 diabetes

Absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among those with the condition, according to a new meta-analysis.
12 Aug 2022

GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases

A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
8 Apr 2022

SGLT-2 inhibitors associated with reduced heart failure events versus metformin

A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
10 Jun 2022

Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says

Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
10 Jun 2022

DPP-4 inhibitors associated with risk of cholecystitis, meta-analysis finds

Patients with type 2 diabetes who were randomized to receive dipeptidyl peptidase-4 (DPP-4) inhibitors had higher rates of gallbladder disease than those who got placebo or nonincretin drugs, but no difference in risk of cholelithiasis or biliary diseases.
8 Jul 2022

Statins compared for non-HDL cholesterol levels in patients with diabetes

Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
8 Apr 2022

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next